Public Employees Retirement System of Ohio Grows Stock Position in Jazz Pharmaceuticals PLC $JAZZ

Public Employees Retirement System of Ohio increased its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 1.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,752 shares of the specialty pharmaceutical company’s stock after purchasing an additional 252 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Jazz Pharmaceuticals were worth $2,096,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also bought and sold shares of the company. Cardinal Capital Management boosted its position in Jazz Pharmaceuticals by 5.6% during the 2nd quarter. Cardinal Capital Management now owns 13,997 shares of the specialty pharmaceutical company’s stock valued at $1,485,000 after acquiring an additional 743 shares in the last quarter. Park Avenue Securities LLC purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter valued at $336,000. BTC Capital Management Inc. raised its stake in Jazz Pharmaceuticals by 2.3% during the 2nd quarter. BTC Capital Management Inc. now owns 50,478 shares of the specialty pharmaceutical company’s stock valued at $5,330,000 after buying an additional 1,125 shares during the last quarter. CX Institutional raised its stake in Jazz Pharmaceuticals by 23.4% during the 2nd quarter. CX Institutional now owns 42,892 shares of the specialty pharmaceutical company’s stock valued at $4,552,000 after buying an additional 8,124 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of Jazz Pharmaceuticals by 25.3% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 5,429 shares of the specialty pharmaceutical company’s stock worth $594,000 after purchasing an additional 1,095 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently weighed in on JAZZ. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a “buy” rating and a $152.00 target price on the stock. Truist Financial increased their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Morgan Stanley raised their target price on shares of Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Finally, The Goldman Sachs Group increased their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a research note on Friday, August 29th. Fourteen equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $178.93.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the sale, the director owned 429,973 shares of the company’s stock, valued at $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Stock Up 0.2%

JAZZ stock opened at $137.21 on Friday. The stock has a market capitalization of $8.32 billion, a P/E ratio of -20.39, a P/E/G ratio of 8.49 and a beta of 0.28. The firm has a 50-day simple moving average of $123.33 and a 200-day simple moving average of $115.84. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.